 This is a Phase 1, open-label all people know the identity of the intervention, randomized study medication assigned to participants by chance, 2-panel, 3-way crossover participants will receive different interventions sequentially during the trial study in healthy adult participants. Participants will be equally divided over 2 panels, and will not be randomized between panels. Participants will not be allowed to switch panels. The study consists of 3 parts: Screening Phase that is, 28 days before study commences on Day 1; Open-label Treatment in subsequent 3-treatment periods in each Panel, each separated with washout period of 7 days; and Post-Treatment Phase up to 7 days after last study drug intake. The duration of the study per participant will be at least 19 days, screening and follow-up not included. All the eligible participants will be randomly assigned to 1 of the 6 treatment sequences in each Panel. In fasted conditions, study drug will be administered following a 10-hour overnight fast. In fed conditions, participants will also fast from food for 10 hours, but will consume a high fathigh calorie breakfast within a 30-minute period. Study drug will be administered 30 minutes after the start of breakfast. Participants will not be allowed to have food until at least 4 hours after study drug administration. Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment. Relative bioavailability of SMV formulations will be evaluated primarily. Participants safety will be monitored throughout the study. 